This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
MiPLA
Revision as of 23:08, 15 January 2019 by >Unity(Removed approval headerpanel.)
N-Methyl-N-isopropyllysergamide (also known as methylisopropyllysergamide, Lamide and MIPLA) is a novel psychedelic substance of the lysergamide class. MIPLA is chemically similar to LSD and has a similar mechanism of action, working primarily by binding to the serotonin-2A receptor in the brain.[citation needed]
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
MIPLA was first discovered by Albert Hoffman as a part of the original structure-activity research for LSD. It has recently been researched in greater detail by by a team led by David E. Nichols at Purdue University. MIPLA and its effects are also mentioned in Alexander Shulgin's "Pharmacology Notes #9" and "Pharmacology Notes C".[1][2] According to Shulgin, human subjects administered MIPLA at doses of 180–300 μg experienced LSD-like psychedelic effects, making it about two- to threefold less potent than LSD.[3]
User reports describe the effects of MIPLA as similar to those of LSD, with some notable differences. MIPLA has been described as being more mentally and physically oriented but with a less introspective headspace accompanied by subtle visuals. It also has a notably shorter duration at 4-6 hours and is generally described as less anxiety-provoking than LSD and other lysergamides.
Very little data exists about the pharmacological properties, metabolism, and toxicity of MIPLA. It is highly advised to use harm reduction practices when using this substance.
The chemical name of MIPLA is methylisopropyllysergamide. MIPLA belongs to a class of organic compounds known as lysergamides, which are a subclass of ergolines (derivatives of the alkaloids found in the ergot fungus). The most prominent member of the lysergamides is LSD, lysergic acid diethylamide.
MIPLA is a structural isomer of LSD. Like LSD, the chemical structure of MIPLA is based on the lysergic acid amide structural skeleton. However, whereas LSD has two ethyl groups bound to the amide nitrogen, MIPLA is substituted with a methyl and isopropyl group.
MIPLA is a chiral compound with two stereocenters at R5 and R8. The differences in psychoactivity between the stereoisomers have not been investigated.
Pharmacology
As with its structurally related lysergamides, MIPLA principally acts as a 5-HT2A partial agonist, through which it exerts its psychedelic effects. However, the role of these interactions and how they result in the psychedelic experience is unclear.
MIPLA is commonly reported to be significantly shorter in its duration and less uncomfortable in both its negative physical side effects and general anxiety.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
Stimulation - MIPLA is considered to be primarily stimulating in nature in the same vein as LSD. This is in distinction to other, more commonly used psychedelics such as psilocybin which are more consistent in producing sedation and relaxedness.
Spontaneous bodily sensations - The "body high" of MIPLA can be described as proportionally intense in comparison to its accompanying visual and cognitive effects. It behaves as a pleasurable, fast-moving, sharp and location specific tingling sensation. For some, it is manifested spontaneously at different unpredictable points throughout the experience, but for most it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. In comparison to LSD, MIPLA is a little less sharp in the tingling sensations it produces as but is otherwise essentially indistinguishable.
Physical euphoria - Physical euphoria on MIPLA is not as consistent as it is with substances like stimulants or entactogens, and can just as easily manifest as physical discomfort without any apparent reason.
Changes in felt bodily form - This effect is often accompanied by a sense of warmth or unity and usually occurs during and up to the peak of the experience or directly afterward. Users can feel as if they are physically part of or conjoined with other objects. This is usually reported as feeling comfortable and peaceful in its sensations.
Tactile enhancement - Feelings of enhanced tactile sensations are consistently present at moderate levels throughout most MIPLA trips.
Seizure[citation needed] - The possibility of seizures is extrapolated from the seizures that have been reported following the use of LSD. They are thought to mainly be a risk in those who are genetically predisposed to them, particularly while accompanied by physically taxing conditions such as dehydration, fatigue or undernourishment.
Drifting(melting, breathing, morphing and flowing) - In comparison to other psychedelics, this effect can be described as highly detailed yet cartoon-like in appearance. The distortions are slow and smooth in motion and fleeting in their appearance. This is nearly identical in appearance to the visual drifting which occurs under the influence of LSD.
The visual geometry evoked by MIPLA can be described as more similar in appearance to that of LSD, 2C-B or 4-HO-MET than psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful and cartoonish in scheme, organic in feel, flat in shading, soft in its edges, large in size, slow in speed, smooth in motion, either angular or round in its corners, non-immersive in-depth and consistent in intensity. At higher dosages, it consistently results in states of Level 8B visual geometry over Level 8A.
In comparison to LSD specifically, MIPLA's geometry tends to be more rounded in its corners, slightly softer in its edges, warmer in hue, and slightly less intricate in its form. Aside from this, it is otherwise identical in its appearance.
Hallucinatory states
MIPLA is capable of producing a full range of low and high level hallucinatory states in a fashion that is a less consistent and reproducible than that of many other commonly used psychedelics such as psilocin or DMT but considerably more likely to when compared to that of LSD. This can feel similar to the hallucinations which occur with 4-AcO-DMT but tends to occur almost exclusively at heavierdoses. Some of these effects include:
Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - This effect is very consistent in dark environments at appropriately high dosages. They can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and occasionally of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
Reports indicate that the transpersonal effects of MIPLA are comparatively weaker than those of LSD and other lysergamides, as well as classical psychedelics such as psilocybin mushrooms or mescaline.
The toxicity and long-term health effects of recreational MIPLA use has not been studied in any scientific context and the exact toxic dose is unknown. This is because MIPLA is a research chemical with very little history of human usage.
The body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
However, as is the case for LSD, it is possible that MIPLA can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.
The LD50 of MIPLA is unknown. Adverse psychological reactions may be more likely to occur at higher doses. Some of these include anxiety, delusions, panic attacks and more rarely seizures. Medical attention is usually only needed if suspected of severe psychotic episodes or “fake acid” (such as 25i-NBOMe or DOB). Administration of benzodiazepines or antipsychotics can help to relieve the negative cognitive effects of MIPLA.
Dependence and abuse potential
Although no formal studies have been conducted, it is not unreasonable to assume that as with LSD itself, MIPLA is not habit-forming and that the desire to use it can actually decrease with use.
Tolerance to the effects of MIPLA are built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). MIPLA presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the use of MIPLA all psychedelics will have a reduced effect.
Owing to its activity at the 5-HT2A receptor, MIPLA presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of MIPLA all psychedelics will have a reduced effect.
Dangerous interactions
Warning:Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Lithium - Individuals who take lithium for bipolar disorder or other psychiatric conditions should not take MIPLA. There are numerous anecdotal reports of individuals experiencing seizures and/or psychosis from the combination of LSD and lithium.[4][5][6][7] Due to MIPLA's chemical similarity to LSD, it is assumed to carry a similar risk.
Tramadol - Tramadol lowers the seizure threshold[8] and psychedelics may act as triggers for seizures, particularly in predisposed individuals.[citation needed]
Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.[citation needed]
As such, it may contain incomplete or wrong information. You can help by expanding it.
MIPLA currently exists in a legal grey area in most parts of the world. This means that it is not specifically illegal within most countries but individuals may still be charged for its possession under certain circumstances such as under analog laws and with the intent to sell or consume.
Austria: MIPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD. [citation needed]
United States: MIPLA is not scheduled but may be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.
Halberstadt, A. L., Klein, L. M., Chatha, M., Valenzuela, L. B., Stratford, A., Wallach, J., ... & Brandt, S. D. (2018). Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Psychopharmacology, 1-10. http://dx.doi.org/10.1007/s00213-018-5055-9
↑Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
